Cambridge, Mass. • 617-492-5554 • www.molecularinsight.com
Exchange and Ticker: Nasdaq: MIPI
Filing Range: 5M shares @ $14.00 to $16.00
Offering Price: $14.00
Close on First Day: $14.09
Offering Size: $70M
Shares Outstanding: 24,639,622
Underwriters: RBC Capital Markets/ Jefferies & Co. Inc.
Co-managers: AG Edwards & Sons Inc./ Oppenheimer & Co. Inc.
Company Counsel: Foley & Lardner
Manager Counsel: Willkie Farr & Gallagher
Auditor: Deloitte & Touche LLP
Market Capitalization on 2/28/07: $324.75M
Close price at current month end: $13.18
Develops molecular imaging pharmaceuticals and targets radiotherapeutics to diagnose and treat disease. The company’s products are designed to improve the management of disease by targeting, visualizing, treating and monitoring disease at the molecular level. Molecular Insight Pharmaceuticals is also applying its platform technologies to develop targeted radiotherapeutics for the treatment of cancer. Competitors include Bristol-Myers Squibb Imaging, Amersham, GE Healthcare and Tyco Healthcare.
Cerberus Capital Management LP; Emigrant Capital; Siemens Venture Capital GmbH; Tudor Ventures.
Source: Thomson Financial